MedTrace Logo

Treatment of Advanced Intrahepatic Cholangiocarcinoma

NCT03940378 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2019-05-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Levamisole Hcl in the treatment of patients with advanced intrahepatic cholangiocarcinoma.

Conditions

  • ICC

Interventions

DRUG

Levamisole Hydrochloride

Levamisole Hydrochloride Levamisole Hydrochloride 25mg/tablet; 150mg/d; po;

DRUG

Anlotinib Hydrochloride Capsules

Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules 12mg / capsule; 12mg/d; po;

Sponsors & Collaborators

  • First Affiliated Hospital of Xinjiang Medical University

    collaborator OTHER

  • Luoyang Central Hospital

    collaborator OTHER

  • Nanyang Central Hospital

    collaborator OTHER

  • Anyang Tumor Hospital

    collaborator OTHER

  • Third People's Hospital of Jiaozuo

    collaborator UNKNOWN

  • Sanmenxia Central Hospital

    collaborator UNKNOWN

  • pinmei Group General Hospital

    collaborator UNKNOWN

  • The First Affiliated Hospital of Zhengzhou University

    lead OTHER

Principal Investigators

  • Zujiang Yu · The First Affiliated Hospital of Zhengzhou University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2023-02-01
Completion
2023-02-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03940378 on ClinicalTrials.gov